Tags

Type your tag names separated by a space and hit enter

Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration.
Scand J Gastroenterol Suppl. 1986; 119:166-9.SJ

Abstract

We have recently obtained encouraging short-term results after a single subcutaneous injection of the long-acting somatostatin analogue SMS 201-995 in acromegalic patients. Increased growth hormone (GH) levels may be involved in the pathogenesis of proliferative retinopathy in type I diabetes mellitus. In this study we thus investigated the effect of 3 X 50 micrograms SMS 201-995 daily on the metabolic control and hormone secretion of eight type I diabetics over a 3-day period. GH levels decreased by 32% (p less than 0.05) and somatomedin C levels by 31% (p less than 0.01) on the 3rd day of treatment compared with a control day. The insulin requirements during conventional subcutaneous insulin therapy were reduced by 28% (p less than 0.01) in seven patients without deterioration of metabolic control (mean blood glucose levels, 153.8) versus 154.7 mg/dl). Triiodothyronine, thyroxine, glucagon, prolactin, luteinizing hormone and follicle-stimulating hormone showed no significant changes. We conclude that SMS 201-995 could be an excellent tool for further clinical investigation and therapy of diabetic vascular complications.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

2876502

Citation

Plewe, G, et al. "Somatostatin Analogue SMS 201-995 in Type I Diabetes Mellitus. Initial Experience After Repeated Administration." Scandinavian Journal of Gastroenterology. Supplement, vol. 119, 1986, pp. 166-9.
Plewe G, Nölken G, Krause U, et al. Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration. Scand J Gastroenterol Suppl. 1986;119:166-9.
Plewe, G., Nölken, G., Krause, U., del Pozo, E., & Beyer, J. (1986). Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration. Scandinavian Journal of Gastroenterology. Supplement, 119, 166-9.
Plewe G, et al. Somatostatin Analogue SMS 201-995 in Type I Diabetes Mellitus. Initial Experience After Repeated Administration. Scand J Gastroenterol Suppl. 1986;119:166-9. PubMed PMID: 2876502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration. AU - Plewe,G, AU - Nölken,G, AU - Krause,U, AU - del Pozo,E, AU - Beyer,J, PY - 1986/1/1/pubmed PY - 1986/1/1/medline PY - 1986/1/1/entrez SP - 166 EP - 9 JF - Scandinavian journal of gastroenterology. Supplement JO - Scand J Gastroenterol Suppl VL - 119 N2 - We have recently obtained encouraging short-term results after a single subcutaneous injection of the long-acting somatostatin analogue SMS 201-995 in acromegalic patients. Increased growth hormone (GH) levels may be involved in the pathogenesis of proliferative retinopathy in type I diabetes mellitus. In this study we thus investigated the effect of 3 X 50 micrograms SMS 201-995 daily on the metabolic control and hormone secretion of eight type I diabetics over a 3-day period. GH levels decreased by 32% (p less than 0.05) and somatomedin C levels by 31% (p less than 0.01) on the 3rd day of treatment compared with a control day. The insulin requirements during conventional subcutaneous insulin therapy were reduced by 28% (p less than 0.01) in seven patients without deterioration of metabolic control (mean blood glucose levels, 153.8) versus 154.7 mg/dl). Triiodothyronine, thyroxine, glucagon, prolactin, luteinizing hormone and follicle-stimulating hormone showed no significant changes. We conclude that SMS 201-995 could be an excellent tool for further clinical investigation and therapy of diabetic vascular complications. SN - 0085-5928 UR - https://www.unboundmedicine.com/medline/citation/2876502/Somatostatin_analogue_SMS_201_995_in_type_I_diabetes_mellitus__Initial_experience_after_repeated_administration_ DB - PRIME DP - Unbound Medicine ER -